T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an international, multicenter, randomized study of intravenous T138067 versus
intravenous doxorubicin in hepatocellular carcinoma (liver cancer). Patients can not have
been treated before with chemotherapy and surgery is not recommended for their cancer. A
total of 750 subjects will be enrolled in this study.